1407 GMT - Bayer raised its full-year guidance, but the increase seems to reflect the margin by which its third-quarter earnings beat expectations, analysts at Jefferies write in a note to clients. A strong performance in the German company's pharmaceutical division drove group-level adjusted Ebitda to exceed consensus estimates by 14%, or 200 million euros, the analysts say. This could be the result of one-off items, as the group's quarterly core EPS missed expectations, they add. Since Bayer raised its full-year adjusted Ebitda guidance by 200 million euros, it seems like it only took the size of its third-quarter beat forward into the full year, according to Jefferies. Shares rise 6.6%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments